Walleye Capital LLC Sells 905,744 Shares of Unicycive Therapeutics, Inc. $UNCY

Key Points

• Walleye Capital LLC has reduced its stake in Unicycive Therapeutics by 18.1%, holding approximately 4.09 million shares worth $2.35 million after the first quarter.
• Several hedge funds have increased their positions, with notable boosts from Octagon Capital Advisors (16.8%) and Vivo Capital LLC (14.0%).
• Wall Street analysts have mixed views on the stock, with ratings ranging from a sell to a strong-buy, and a consensus price target set at $60.00.

Walleye Capital LLC cut its stake in Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) by 18.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,094,256 shares of the company's stock after selling 905,744 shares during the period. Walleye Capital LLC owned 3.39% of Unicycive Therapeutics worth $2,354,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of UNCY. Vivo Capital LLC raised its stake in shares of Unicycive Therapeutics by 14.0% during the first quarter. Vivo Capital LLC now owns 11,370,152 shares of the company's stock worth $6,537,000 after buying an additional 1,400,000 shares during the last quarter. Octagon Capital Advisors LP raised its stake in shares of Unicycive Therapeutics by 16.8% during the fourth quarter. Octagon Capital Advisors LP now owns 10,000,000 shares of the company's stock worth $7,942,000 after buying an additional 1,441,000 shares during the last quarter. Acuta Capital Partners LLC raised its stake in shares of Unicycive Therapeutics by 16.4% during the fourth quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company's stock worth $1,829,000 after buying an additional 323,801 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Unicycive Therapeutics by 30.3% during the fourth quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock worth $417,000 after buying an additional 122,089 shares during the last quarter. Finally, Northern Trust Corp raised its stake in shares of Unicycive Therapeutics by 142.4% during the fourth quarter. Northern Trust Corp now owns 58,181 shares of the company's stock worth $46,000 after buying an additional 34,183 shares during the last quarter. 40.42% of the stock is owned by institutional investors.

Unicycive Therapeutics Stock Down 0.5%

UNCY traded down $0.02 during trading hours on Wednesday, hitting $4.30. 65,174 shares of the company's stock were exchanged, compared to its average volume of 371,700. Unicycive Therapeutics, Inc. has a 1-year low of $2.83 and a 1-year high of $11.00. The stock's 50-day moving average is $4.59 and its two-hundred day moving average is $5.56. The stock has a market cap of $75.94 million, a price-to-earnings ratio of -1.05 and a beta of 1.87.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.70) by $0.18. On average, equities research analysts anticipate that Unicycive Therapeutics, Inc. will post -0.23 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on UNCY. HC Wainwright raised shares of Unicycive Therapeutics to a "strong-buy" rating and set a $90.00 price target for the company in a research note on Tuesday, May 27th. Wall Street Zen raised shares of Unicycive Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday. One analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $60.00.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.